Shilpa Biologicals files Type IV DMF of recombinant Human Albumin 20% with USFDA

This novel recombinant has been developed and is a patented novel recombinant Human Albumin 20% process

Shilpa Biologicals, a wholly owned subsidiary of Shilpa Medicare has filed its first Drug Master File of recombinant Human Albumin 20% with USFDA.

This novel recombinant has been developed and is a patented novel recombinant Human Albumin 20% process which is completely environment friendly, consistent high quality product, scalable to massive scales and is cost competitive.

Recombinant Human Albumin 20% targets to fulfil growing demand of human serum albumin to deliver current and growing market demand.